The Munich techbio company is developing a live bacterial product designed to enhance immune checkpoint inhibitor response in advanced melanoma, with a Phase 1B study planned for 2027 mbiomics GmbH, a Munich-based techbio company developing microbiome-based therapeutics, has completed the third and final closing of its Series A funding round, bringing the total raised to […] This story continues at The Next Web